Bluebird Preamble Sample Clauses

Bluebird Preamble. Bluebird In-Licensed IP Section 1.5 Bluebird Development Cap Section 4.3(c)(i) Bluebird Indemnitees Section 16.6(a) Bluebird Licensed IP Section 1.6 Bluebird Regulatory Rights Section 1.7 Bluebird Technology Section 1.8 Budgeted U.S. Development Costs Section 4.3 Business Acquisition Section 10.4 Business Party Section 10.4 Business Program Section 10.4 CCPS Agreement Preamble CCPS Agreement Effective Date Preamble CCPS Agreement Term Section 17.1 Celgene Preamble Celgene Corp Preamble Celgene Europe Preamble Celgene Indemnitees Section 16.6(b) Celgene Licensed IP Section 1.9 Celgene Licensed Product In-License Section 1.10 Celgene Licensed Product In-Licensed IP Section 1.11 Celgene Other In-License Section 1.13 Celgene Regulatory Rights Section 1.14 Celgene Technology Section 1.15

Bluebird Preamble. Bluebird In-Licensed IP Section 1.5 Bluebird Indemnitees Section 16.7(a) Bluebird Licensed IP Section 1.6 Bluebird Regulatory Rights Section 1.7 Bluebird Technology Section 1.8 Budgeted U.S. Development Costs Section 4.3 Business Acquisition Section 10.4 CONFIDENTIAL TREATMENT REQUESTED BY BLUEBIRD BIO, INC. [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED Defined Terms Location Business Party Section 10.4 Business Program Section 10.4 CCPS Agreement Preamble CCPS Agreement Effective Date Preamble CCPS Agreement Term Section 17.1 Celgene Preamble Celgene Corp Preamble Celgene Europe Preamble Celgene Indemnitees Section 16.7(b) Celgene Licensed IP Section 1.9 Celgene Licensed Product In-License Section 1.11 Celgene Licensed Product In-Licensed IP Section 1.12 Celgene Other In-License Section 1.14 Celgene Regulatory Rights Section 1.15 Celgene Technology Section 1.16 Clinical Study Section 1.17 Co-Co In Licenses Section 8.1 Combination Product Section 1.36 Commercialization Section 1.18 Commercially Reasonable Efforts Section 1.19 Competitive Infringement Section 14.1 Control Section 1.20 Cost of Goods Sold or COGS Appendix F Covers Section 1.21 Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A EU Section 1.23 EU Regulatory Event Section 1.24 Field Section 1.25 First Commercial Sale Section 1.26 First Indication Section 1.27 Fully Burdened Manufacturing Cost Appendix I GAAP Section 1.28 Gene Editing Section 1.31 Gross Profit Appendix F Gross Sales Appendix F In-License Payment Section 1.32 CONFIDENTIAL TREATMENT REQUESTED BY BLUEBIRD BIO, INC. [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED Defined Terms Location Indemnification Claim Notice Section 16.7(c) Indemnified Party Section 16.7(c) Information Request Section 5.6(g) JGC Section 3.1(a) Joint IP Section 12.2 Licensed IP Section 1.33 Licensed Product Section 1.34 Losses Section 16.7(a) Major EU Countries Section 1.24 Manufacturing Section 1.35 Manufacturing and Supply Agreement Section 7.4(b)(ii) Marke...